Biocatalysis and Catalysis in Islatravir Synthesis | Merck Webinar

Added:

Developmental and Downstream Bottlenecks of Custom Biocatalytic Cascades

While Merck's multi-enzymatic synthesis of Islatravir showcases the potential of biocatalysis, critics and traditional synthetic chemists highlight significant practical and economic trade-offs. First, the directed evolution of bespoke enzymes requires immense upfront investment, specialized expertise, and time, making it less viable for early-to-mid-phase drug development where rapid iteration is crucial. Second, biocatalytic reactions typically operate in highly dilute aqueous environments. This introduces severe downstream processing (DSP) challenges, as isolating hydrophilic active pharmaceutical ingredients (APIs) from water is highly energy-intensive and generates substantial aqueous waste. Consequently, when considering the entire life-cycle analysis, traditional transition-metal or organocatalytic routes—which offer broader substrate scope, higher concentration limits, and more straightforward purification protocols—often remain more economically and logistically viable for many pharmaceutical pipelines.

Fundamentals of Biocatalysis: Understanding how enzymes function as highly selective catalysts, including substrate specificity, enzyme kinetics, and active site interactions.
Basic Organic Chemistry and Catalytic Mechanisms: Familiarity with transition metal catalysis, oxidation-reduction reactions, and common synthetic organic pathways.
Structure and Chemistry of Nucleoside Analogs: Conceptual understanding of nucleoside structures (sugar-base pairings) and how nucleoside analogs function in biochemistry.
Principles of Green Chemistry: Familiarity with the concepts of atom economy, step economy, and minimizing hazardous waste in chemical synthesis.
Enzymatic Cascade Reactions: Exploring the design of one-pot, multi-step enzymatic pathways where products of one enzyme reaction serve as substrates for the next.
Directed Evolution for Industrial Biocatalysis: Studying how techniques like directed evolution (e.g., Arnold's Nobel-winning method) are used to engineer custom enzymes for synthetic routes.
Industrial Scale-up and Process Chemistry: Investigating the challenges of transitioning lab-scale catalytic reactions into robust, safe, and cost-effective multi-ton pharmaceutical manufacturing processes.
Mechanism of Action of Islatravir (EFdA): Studying how this nucleoside reverse transcriptase translocation inhibitor (NRTI) blocks HIV replication at the molecular level.
675 views11likes1:23:56@SCIwheresciencemeetsbusinessOriginal Release: 2020-10-08

This webinar presents Merck's innovative approach to synthesizing the HIV drug candidate islatravir using a fully enzymatic cascade reaction that combines phosphorylase, mutase, aldolase, and galactose oxidase enzymes with directed evolution techniques. The cascade converts simple building blocks (glyceraldehyde, acetaldehyde, and base) into the complex deoxyribonucleoside analog through multiple enzymatic steps operating in a single solvent stream without intermediate isolation. This biocatalytic approach dramatically improves efficiency compared to traditional 12-18 step chemical syntheses, reducing process mass intensity by approximately 15-fold and increasing overall yield by nearly four-fold. The presentation also explores complementary strategies including transition metal catalysis and electrochemical approaches for asymmetric oxidation, demonstrating how integrating different catalytic paradigms enables sustainable synthesis of complex pharmaceutical molecules.